Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered
            <i>circPRMT5</i>
            siRNA

Yu, Chunping; Zhang, Yi; Wang, Ning; Wei, Wensu; Cao, Ke; Zhang, Qun; Ma, Peiying; Xie, Dan; Wu, Pei Hsun; Liu, Biao; Xiang, Wei; Hu, Xing; Li, Xuewen; Xie, Jianfei; Tang, Jin; Li, Zhi; Wang, Long; Zeng, Hongliang; Liu, Jianye

doi:10.1186/s40824-022-00251-z

Cited by 16 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gene therapy: Gene therapy has become an exciting therapeutic area in cancer treatment because of the ineffectiveness of conventional therapies to precisely target tumor cells. 154 By injecting therapeutic nucleic acids, gene therapy aims to eliminate disease-causing cells or alter immune responses. A significant obstacle in cancer gene therapy is the implementation of small interfering RNAs (siRNAs) or miRNAs to address cancer cells.…”

Section: Using Nanomedicine For Bladder Cancer Therapymentioning

confidence: 99%

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Sharma,

Malviya

2023

Precision Medical Sciences

View full text Add to dashboard Cite

Bladder cancer (BC) accounts for roughly 3% of all cancer diagnoses in developed countries. The prognosis could be improved significantly if the cancer is detected and classified as either muscle‐invasive bladder cancer (MIBC) or non‐muscle‐invasive bladder cancer (NMIBC) as promptly as possible. A potential ray of hope for the treatment of BC has emerged with the rapid development of nanomedicine and microRNAs (miRNAs), which promise to have fewer adverse effects, more tumor‐inhibitory effects, and decreased drug resistance. The complex interplay between hereditary and environmental variables is the root cause of this malignancy. Gene expression can be regulated by miRNAs, which are small, non‐coding RNAs that can either prevent the translation of protein‐coding genes or cleave RNA transcripts at certain locations. Elevated genomics has enabled a more extensive investigation of miRNAs whose expression is considerably different in BC patients compared to healthy volunteers or between BC tumor tissues and peripheral tissues. miRNAs have recently been discovered to be important regulators of BC cell carcinogenicity. Inaccurate diagnoses and prolonged treatment delays are more likely to occur due to the current diagnostic process such as lack of sensitivity and specificity and poor image quality. Patients now have access to a plethora of treatment options, including but not limited to surgery, chemotherapy, immunotherapy, gene therapy, and other innovative medicines, and in some cases, combination therapies. BC is one of the deadliest and most disabling malignancies affecting the urinary tract. Cancer of the urinary bladder has a terrible propensity for being fatal. BC is an intricate illness whose development can be affected by multiple parameters. Standard treatments for BC increase prognosis and survival, although recurrence is a major concern for patients. miRNAs are naturally occurring, small RNA molecules that have been linked to cancer through their expression being dysregulated. miRNAs modulate many cellular activities including proliferation, migration, differentiation, and apoptosis. MiRNA dysregulation is recognized in BC, and miRNAs are used as diagnostic and prognostic indicators. However, this manuscript discusses the recent progress made in nanomedicine and the function of miRNAs in the pathogenesis and targeted therapy of BC.

show abstract

Section: Using Nanomedicine For Bladder Cancer Therapymentioning

confidence: 99%

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Sharma,

Malviya

2023

Precision Medical Sciences

View full text Add to dashboard Cite

show abstract

“…The nanoparticles demonstrated high safety profile and suppressed proliferation and invasion of bladder cancer cells. 94 …”

Section: Nanoplatforms In Gene Deliverymentioning

confidence: 99%

“…The nanoparticles demonstrated high safety profile and suppressed proliferation and invasion of bladder cancer cells. 94 Exosomes are emerging nanostructures belonging to extracellular vesicles (EVs) with sizes smaller than 100 nm and can transfer lipids, proteins, and nucleic acids among cells. 95 Exosomes are potential therapeutic agents in bladder cancer, and they can be used for siRNA delivery in tumor suppression.…”

Section: Nanoplatforms In Gene Deliverymentioning

confidence: 99%

(Nano)platforms in bladder cancer therapy: Challenges and opportunities

Ashrafizadeh

Zarrabi

Karimi‐Maleh

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

Urological cancers are among the most common malignancies around the world. In particular, bladder cancer severely threatens human health due to its aggressive and heterogeneous nature. Various therapeutic modalities have been considered for the treatment of bladder cancer although its prognosis remains unfavorable. It is perceived that treatment of bladder cancer depends on an interdisciplinary approach combining biology and engineering. The nanotechnological approaches have been introduced in the treatment of various cancers, especially bladder cancer. The current review aims to emphasize and highlight possible applications of nanomedicine in eradication of bladder tumor. Nanoparticles can improve efficacy of drugs in bladder cancer therapy through elevating their bioavailability. The potential of genetic tools such as siRNA and miRNA in gene expression regulation can be boosted using nanostructures by facilitating their internalization and accumulation at tumor sites and cells. Nanoparticles can provide photodynamic and photothermal therapy for ROS overgeneration and hyperthermia, respectively, in the suppression of bladder cancer. Furthermore, remodeling of tumor microenvironment and infiltration of immune cells for the purpose of immunotherapy are achieved through cargo‐loaded nanocarriers. Nanocarriers are mainly internalized in bladder tumor cells by endocytosis, and proper design of smart nanoparticles such as pH‐, redox‐, and light‐responsive nanocarriers is of importance for targeted tumor therapy. Bladder cancer biomarkers can be detected using nanoparticles for timely diagnosis of patients. Based on their accumulation at the tumor site, they can be employed for tumor imaging. The clinical translation and challenges are also covered in current review.

show abstract

“…Gene therapy that applies nucleic acids such as plasmid DNA (pDNA) and small interfering RNA (siRNA) to cure cancers is regarded to be a promising therapeutic method [ 234 , 235 ]. However, several notable limitations including rapid enzymatic degradation and low intracellular uptake rate still limit the therapeutic efficacy [ 236 , 237 ].…”

Section: Hollow Nanoplatforms For Nir-ii Ptt-based Multi-modal Therapiesmentioning

confidence: 99%

Recent advances in near-infrared-II hollow nanoplatforms for photothermal-based cancer treatment

et al. 2022

View full text Add to dashboard Cite

Near-infrared-II (NIR-II, 1000–1700 nm) light-triggered photothermal therapy (PTT) has been regarded as a promising candidate for cancer treatment, but PTT alone often fails to achieve satisfactory curative outcomes. Hollow nanoplatforms prove to be attractive in the biomedical field owing to the merits including good biocompatibility, intrinsic physical-chemical nature and unique hollow structures, etc. On one hand, hollow nanoplatforms themselves can be NIR-II photothermal agents (PTAs), the cavities of which are able to carry diverse therapeutic units to realize multi-modal therapies. On the other hand, NIR-II PTAs are capable of decorating on the surface to combine with the functions of components encapsulated inside the hollow nanoplatforms for synergistic cancer treatment. Notably, PTAs generally can serve as good photoacoustic imaging (PAI) contrast agents (CAs), which means such kind of hollow nanoplatforms are also expected to be multifunctional all-in-one nanotheranostics. In this review, the recent advances of NIR-II hollow nanoplatforms for single-modal PTT, dual-modal PTT/photodynamic therapy (PDT), PTT/chemotherapy, PTT/catalytic therapy and PTT/gas therapy as well as multi-modal PTT/chemodynamic therapy (CDT)/chemotherapy, PTT/chemo/gene therapy and PTT/PDT/CDT/starvation therapy (ST)/immunotherapy are summarized for the first time. Before these, the typical synthetic strategies for hollow structures are presented, and lastly, potential challenges and perspectives related to these novel paradigms for future research and clinical translation are discussed. Graphical Abstract

show abstract

Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered circPRMT5 siRNA

Cited by 16 publications

References 40 publications

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

(Nano)platforms in bladder cancer therapy: Challenges and opportunities

Recent advances in near-infrared-II hollow nanoplatforms for photothermal-based cancer treatment

Contact Info

Product

Resources

About